Both Fidaxomicin and Vancomycin Inhibit Outgrowth of Clostridium difficile Spores | Zendy

Charlotte A. Allen | Zendy; Farah Babakhani | Zendy; Pam Sears | Zendy; Ly Nguyen | Zendy; Joseph A. Sorg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Both Fidaxomicin and Vancomycin Inhibit Outgrowth of Clostridium difficile Spores

Author(s) -

Charlotte A. Allen,

Farah Babakhani,

Pam Sears,

Ly Nguyen,

Joseph A. Sorg

Publication year - 2012

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01611-12

Subject(s) - fidaxomicin , vancomycin , clostridium difficile , spore , microbiology and biotechnology , germination , diarrhea , spore germination , metabolite , medicine , clostridium , clostridiaceae , biology , bacteria , antibiotics , staphylococcus aureus , toxin , botany , genetics

Fidaxomicin (FDX) is approved to treat Clostridium difficile-associated diarrhea and is superior to vancomycin in providing a sustained clinical response (cure without recurrence in the subsequent 25 days). The mechanism(s) behind the low recurrence rate of FDX-treated patients could be multifactorial. Here, we tested effects of FDX, its metabolite OP-1118, and vancomycin on spore germination and determined that none affected the initiation of spore germination but all inhibited outgrowth of vegetative cells from germinated spores.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research